The EU’s biggest overhaul of packaging law in three decades became binding on August 12, 2026. The Packaging and Packaging Waste Regulation (PPWR) replaces the 1994 Packaging Directive with a single rulebook that applies the same way in all 27 member states — no more country-by-country interpretation. For pharmaceutical and life sciences organizations, PPWR pharmaceutical packaging obligations are now live, even though the full timeline stretches out to 2040.
What Is the EU Packaging and Packaging Waste Regulation (PPWR)?
PPWR — formally Regulation (EU) 2025/40 — entered into force on February 11, 2025, giving industry an 18-month runway before it began applying this week.
As a regulation rather than a directive, PPWR takes effect directly across the bloc, closing the gaps that let member states set their own packaging rules under the old system.
Its stated goals: cut packaging waste, push more packaging toward recyclability, raise the amount of recycled material going into new packaging, and get reuse systems established where they make sense — all under the umbrella of the EU’s Circular Economy Action Plan. The European Commission published implementation guidance in June 2026 aimed at clarifying selected provisions and supporting more consistent application across member states.
What PPWR Requires Starting August 12, 2026
A few obligations are live now rather than years away:
- Declarations of Conformity. Companies placing packaging on the EU market must have a Declaration of Conformity and supporting technical documentation for each packaging type, ready to produce on request from national authorities.
- PFAS restrictions. New limits on per- and polyfluoroalkyl substances (PFAS) took effect as of August 12, 2026.
- Substances of Concern (SoC) minimization. Manufacturers must now identify and minimize substances of concern present in their packaging — this applies to all packaging placed on the EU market, including packaging that benefits from the Article 6(7) recyclability exemption. PPWR does not yet define a fixed SoC list or universal concentration threshold, but documentation must be available in technical files and supplier records now, and authorities may request evidence of minimization at any time.
Bigger changes — minimum recycled-content targets, reuse-system mandates, packaging space-efficiency limits, and the “recyclable by design” requirement — phase in between 2027 and 2035, with a further “recyclable at scale” bar in 2035 and full harmonized labeling and registries following after that.
Does PPWR Exempt Pharmaceutical Packaging?
This is the detail generic PPWR coverage often glosses over, and it’s the one that matters most to this audience. PPWR does not exempt pharmaceutical companies wholesale. Instead, under Article 6(7), it exempts specific packaging:
- Immediate packaging in direct contact with the medicinal product.
- Packaging necessary to preserve the quality, stability, safety, or efficacy of the medicinal product.
- Certain contact-sensitive packaging for medical devices and in vitro diagnostics (IVDs).
That exemption covers recyclability and recycled-content requirements only. Everything else in PPWR — including substance-of-concern minimization, labeling, extended producer responsibility, and the Declaration of Conformity itself — still applies in full, even to exempted packaging. A blister pack may be exempt from recyclability rules, but it’s not exempt from SoC documentation requirements; the carton it ships in is exempt from neither.
The exemption is also temporary rather than settled policy. It’s scheduled for review in 2035, alongside the “recyclable at scale” requirement that applies to the rest of the market — a signal that today’s exempted materials aren’t guaranteed a permanent pass.
Why PPWR Creates a Compliance Bind for Pharma Companies
Ordinary consumer-goods companies can swap packaging materials relatively quickly. Pharma can’t. Changing a primary packaging material typically triggers a regulatory variation filing and one to three years of real-time stability testing before the European Medicines Agency (EMA) or national authorities will sign off.
That mismatch — a fast-moving sustainability regulation meeting a slow-moving product-approval system — is the central tension industry groups have flagged since PPWR’s pharmaceutical packaging provisions became clearer earlier this year.
For temperature-controlled shipments — biologics, vaccines, cell and gene therapies, clinical trial materials — the stakes are higher still. A packaging solution has to be matched to the product, shipping profile, required temperature range, duration, and distribution environment, and any redesign has to hold up against validated thermal performance and transit-risk testing, not just recyclability criteria.
Peli BioThermal’s Approach
At Peli BioThermal, our focus has always been on protecting life-saving therapies while continuing to advance temperature-controlled packaging solutions. Our portfolio spans parcel-to-pallet shipping solutions, including both reusable and single-use systems designed for different shipping durations and temperature requirements.
Alongside the product line, our repair, conditioning, and refurbishment programs extend the useful life of packaging already in service. Solutions like Vēro One — a single-stream recyclable, flat-packable dry ice shipper — reflect the same direction PPWR is pushing the wider market toward.
That combination is increasingly relevant under PPWR. Customers aren’t only asking how a solution performs during a single shipment — they’re asking how it fits into a broader lifecycle: how long it can remain in service where reuse is appropriate, and how its materials are managed once it’s retired. Our sustainability focus is built around minimizing waste, reducing emissions, and maximizing reliability, with our refurbishment capabilities providing an additional pathway for extending product lifespans where it makes sense for the application.
As PPWR’s requirements continue to phase in, we’ll keep following the regulatory developments that affect temperature-controlled packaging and sharing what we learn with customers operating in or serving European markets.
Key PPWR Deadlines Pharma Supply Chains Should Track
- February 12, 2027. EU member states must have penalty regimes in place for non-compliance — the point at which PPWR obligations carry defined enforcement teeth.
- August 12, 2028. Harmonized labeling requirements, compostable packaging standards, and restrictions on excessive packaging take effect.
- January 1, 2030. Packaging minimization, recyclable-by-design rules, recycled-content obligations, and reusable packaging targets become mandatory — including the 70% recyclability grade threshold below which packaging can’t be placed on the market, and a cap limiting empty space to 50% in e-commerce, grouped, and transport packaging. This doesn’t touch exempted primary pharma packaging directly, but does apply to secondary and tertiary packaging around it.
- 2030–2040. Recyclability, recycled-content, and reuse requirements continue to tighten in stages.
- 2035. The date to plan around: regulators revisit whether the healthcare exemption under Article 6(7) still holds, alongside the “recyclable at scale” bar that applies to the rest of the market.
More guidance is also expected between now and these deadlines — the European Commission’s first implementation guidance came in March 2026 and June 2026, and further clarification, including on how the Article 6(7) safety exemption may be applied in practice, is likely as later deadlines approach.
Bottom Line for Pharma Packaging Teams
PPWR is now enforceable, but for pharmaceutical supply chains, most of the hard decisions are still ahead rather than behind. The exemptions built into the regulation function as a safety valve, not a shield — companies still need documentation, still need to track substance restrictions, and still need to start evaluating recyclable, high-barrier materials now, given how long pharmaceutical packaging changes take to validate and approve.
As therapies evolve, so must the solutions that protect them. Peli BioThermal will continue to monitor PPWR’s rollout and help customers navigate what it means for their supply chains.
This article is intended for general informational purposes and does not constitute legal or regulatory advice. Organizations should assess the applicability of PPWR to their specific packaging, products, markets, and operations with qualified regulatory or legal professionals.
